Advanced in Peripheral T-Cell Lymphoma

Unn-merete Fagerli

St. Olavs Hospital
Trondheim, NO 
Advanced in Peripheral T-Cell Lymphoma
St. Olavs Hospital
Trondheim, NO 
OverviewLocationsClinical Research

Overview

Unn-merete Fagerli practices in Trondheim, Norway. Fagerli is rated as an Advanced expert by MediFind in the treatment of Peripheral T-Cell Lymphoma. Their top areas of expertise are Peripheral T-Cell Lymphoma, T-Cell Lymphoma, Non-Hodgkin Lymphoma, Classical Hodgkin Lymphoma, and Bone Marrow Transplant.

Their clinical research consists of co-authoring 34 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 1 article in the study of Peripheral T-Cell Lymphoma.

Locations

St. Olavs Hospital
Trondheim, Norway

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

IELSG37: A Randomized, Open-label, Multicentre, Two-arm Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma (PMLBCL)
IELSG37: A Randomized, Open-label, Multicentre, Two-arm Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma (PMLBCL)
Enrollment Status: Active_not_recruiting
Publish Date: October 24, 2024
Intervention Type: Radiation, Other
Study Phase: Not Applicable
Phase 1/2 Study of the Combination of Pixantrone, Etoposide, Bendamustine and, in CD20 Positive Tumors, Rituximab in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas of B- or T-cell Phenotype - the P[R]EBEN Study
Phase 1/2 Study of the Combination of Pixantrone, Etoposide, Bendamustine and, in CD20 Positive Tumors, Rituximab in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas of B- or T-cell Phenotype - the P[R]EBEN Study
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2022
Intervention Type: Drug
Study Drug: Rituximab
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

34 Total Publications

Response to Comment on: A simplified frailty score predicts outcome in curatively treated older patients with classical Hodgkin lymphoma.
Response to Comment on: A simplified frailty score predicts outcome in curatively treated older patients with classical Hodgkin lymphoma.
Journal: Haematologica
Published: May 25, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Fagerli's expertise for a condition
ConditionClose
      View All 8 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile